Adverum Biotechnologies is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing therapeutic benefit to patients dealing with chronic or debilitating disease. The company is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Type
Public
HQ
Menlo Park, US
Founded
2006
Size (employees)
61 (est)
Adverum Biotechnologies was founded in 2006 and is headquartered in Menlo Park, US
Report incorrect company information

Key People/Management at Adverum Biotechnologies

Amber Salzman

Amber Salzman

CEO / President
Leone Patterson

Leone Patterson

CFO
Mehdi Gasmi

Mehdi Gasmi

CTO

Adverum Biotechnologies Office Locations

Adverum Biotechnologies has offices in Menlo Park and Philadelphia
Menlo Park, US (HQ)
1035 O'Brien Dr
Show all (2)
Report incorrect company information

Adverum Biotechnologies Financials and Metrics

Adverum Biotechnologies Financials

Adverum Biotechnologies's revenue was reported to be $1.46 m in FY, 2016 which is a 37.3% decrease from the previous period.
USD

EBIT (FY, 2017)

(58.8 m)

Market capitalization (31-Oct-2017)

140.7 m

Closing share price (31-Oct-2017)

3.3

Cash (31-Dec-2017)

70.5 m
Adverum Biotechnologies's current market capitalization is $140.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

572 k2.3 m1.5 m

Revenue growth, %

305%(37%)

General and administrative expense

8 m22.1 m24.4 m

R&D expense

17 m25.5 m31.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

135 k204 k

General and administrative expense

1.5 m2.4 m4.1 m5 m7.6 m8.3 m5.1 m6.1 m8 m4.1 m

R&D expense

3.1 m5.7 m5.6 m5.1 m7.5 m7.5 m8 m8.4 m9.1 m8.5 m

Operating expense total

4.6 m8.1 m9.8 m10.1 m15.2 m15.8 m62.2 m14.9 m17.1 m12.6 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

159.4 m221.3 m222.2 m70.5 m

Inventories

874 k1.5 m2.2 m

Current Assets

160.3 m261 m225.3 m193.7 m

PP&E

1.1 m3.2 m4.2 m3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

52.4 m165.3 m201.8 m200.5 m200.7 m247.1 m241.3 m231.3 m71.6 m39.5 m

Accounts Receivable

8 k8 k

Current Assets

52.9 m166.3 m291.1 m280.6 m270.4 m249.2 m243.6 m235.9 m212.6 m199.6 m

PP&E

509 k817 k1.4 m2.9 m3.3 m3.6 m4 m4.3 m4.1 m3.8 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(25.4 m)(47.5 m)(113.7 m)(56.1 m)

Depreciation and Amortization

162 k812 k1.6 m2.1 m

Inventories

(624 k)(531 k)71 k

Accounts Payable

(6 k)18.2 m(111 k)333 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.1 m)(8.3 m)(9.5 m)(9.8 m)(14.1 m)(15.4 m)(61.7 m)(14.3 m)(16.1 m)

Accounts Payable

1.6 m1.6 m2.8 m1.9 m1.1 m486 k2.4 m3.1 m3.4 m
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Adverum Biotechnologies Operating Metrics

FY, 2016

Patents Issued

12

Patents Pending

60
Show all operating metrics
Report incorrect company information